Hofer Michal, Hoferová Zuzana, Depeš Daniel, Falk Martin
Department of Cell Biology and Radiobiology, Institute of Biophysics, v.v.i., Czech Academy of Sciences, Královopolská 135, 61265 Brno, Czech Republic.
Molecules. 2017 May 19;22(5):834. doi: 10.3390/molecules22050834.
The goal of combined pharmacological approaches in the treatment of the acute radiation syndrome (ARS) is to obtain an effective therapy producing a minimum of undesirable side effects. This review summarizes important data from studies evaluating the efficacy of combining radioprotective agents developed for administration prior to irradiation and therapeutic agents administered in a post-irradiation treatment regimen. Many of the evaluated results show additivity, or even synergism, of the combined treatments in comparison with the effects of the individual component administrations. It can be deduced from these findings that the research in which combined treatments with radioprotectors/radiomitigators are explored, tested, and evaluated is well-founded. The requirement for studies highly emphasizing the need to minimize undesirable side effects of the radioprotective/radiomitigating therapies is stressed.
联合药理学方法治疗急性放射综合征(ARS)的目标是获得一种有效疗法,同时产生最少的不良副作用。本综述总结了评估用于照射前给药的辐射防护剂与照射后治疗方案中使用的治疗剂联合使用疗效的研究中的重要数据。与单独使用各组分的效果相比,许多评估结果显示联合治疗具有相加甚至协同作用。从这些发现可以推断,探索、测试和评估辐射防护剂/辐射缓解剂联合治疗的研究是有充分依据的。强调了对研究的要求,即高度重视尽量减少辐射防护/辐射缓解疗法不良副作用的必要性。